|
1
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kudo I, Esumi M, Kida A and Ikeda M: p53
mutation, but not in vitro predictor genes of therapeutic efficacy
of cisplatin, is clinically relevant in comparing partial and
complete responder cases of maxillary squamous cell carcinoma.
Oncol Rep. 24:851–856. 2010.PubMed/NCBI
|
|
3
|
Bergamaschi D, Gasco M, Hiller L, Sullivan
A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, et
al: p53 polymorphism influences response in cancer chemotherapy via
modulation of p73-dependent apoptosis. Cancer Cell. 3:387–402.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li
W, Wang F and Wu E: Alterations of TP53 are associated with a poor
outcome for patients with hepatocellular carcinoma: Evidence from a
systematic review and meta-analysis. Eur J cancer. 48:2328–2338.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohnishi K, Ota I, Takahashi A, Yane K,
Matsumoto H and Ohnishi T: Transfection of mutant p53 gene
depresses X-ray- or CDDP-induced apoptosis in a human squamous cell
carcinoma of the head and neck. Apoptosis. 7:367–372. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Varna M, Bousquet G, Plassa LF, Bertheau P
and Janin A: TP53 status and response to treatment in breast
cancers. J Biomed Biotechnol. 2011:2845842011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Viktorsson K, De Petris L and Lewensohn R:
The role of p53 in treatment responses of lung cancer. Biochem
Biophys Res Commun. 331:868–880. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zenz T, Krober A, Scherer K, Habe S,
Buhler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwanen C, et
al: Monoallelic TP53 inactivation is associated with poor prognosis
in chronic lymphocytic leukemia: results from a detailed genetic
characterization with long-term follow-up. Blood. 112:3322–3329.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salani R, Kurman RJ, Giuntoli R II,
Gardner G, Bristow R, Wang TL and Shih IM: Assessment of TP53
mutation using purified tissue samples of ovarian serous carcinomas
reveals a higher mutation rate than previously reported and does
not correlate with drug resistance. Int J Gynecol Cancer.
18:487–491. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Steels E, Paesmans M, Berghmans T, Branle
F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ and
Sculier JP: Role of p53 as a prognostic factor for survival in lung
cancer: A systematic review of the literature with a meta-analysis.
Eur Respir J. 18:705–719. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stransky N, Egloff AM, Tward AD, Kostic
AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C,
McKenna A, et al: The mutational landscape of head and neck
squamous cell carcinoma. Science. 333:1157–1160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Agrawal N, Frederick MJ, Pickering CR,
Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, et
al: Exome sequencing of head and neck squamous cell carcinoma
reveals inactivating mutations in NOTCH1. Science. 333:1154–1157.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Westra WH, Taube JM, Poeta ML, Begum S,
Sidransky D and Koch WM: Inverse relationship between human
papillomavirus-16 infection and disruptive p53 gene mutations in
squamous cell carcinoma of the head and neck. Clin Cancer Res.
14:366–369. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
International Union against Cancer: TNM
classification of malignant tumours. Sobin LH, Gospodarowicz MK and
Wittekind C: 7th. Wiley-Blackwell; New York, NY: 2009
|
|
15
|
Takahashi S, Moriya T, Ishida T, Shibata
H, Sasano H, Ohuchi N and Ishioka C: Prediction of breast cancer
prognosis by gene expression profile of TP53 status. Cancer Sci.
99:324–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang KP, Wu CC, Chen HC, Chen SJ, Peng
PH, Tsang NM, Lee LY, Liu SC, Liang Y, Lee YS, et al:
Identification of candidate nasopharyngeal carcinoma serum
biomarkers by cancer cell secretome and tissue transcriptome
analysis: Potential usage of cystatin A for predicting nodal stage
and poor prognosis. Proteomics. 10:2644–2660. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dickinson DP: Cysteine peptidases of
mammals: Their biological roles and potential effects in the oral
cavity and other tissues in health and disease. Crit Rev Oral Biol
Med. 13:238–275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li C, Chen L, Wang J, Zhang L, Tang P,
Zhai S, Guo W, Yu N, Zhao L, Liu M and Yang S: Expression and
clinical significance of cathepsin B and stefin A in laryngeal
cancer. Oncol Rep. 26:869–875. 2011.PubMed/NCBI
|
|
19
|
Parker BS, Ciocca DR, Bidwell BN, Gago FE,
Fanelli MA, George J, Slavin JL, Moller A, Steel R, Pouliot N, et
al: Primary tumour expression of the cysteine cathepsin inhibitor
Stefin A inhibits distant metastasis in breast cancer. J Pathol.
214:337–346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chan TA, Hermeking H, Lengauer C, Kinzler
KW and Vogelstein B: 14-3-3Sigma is required to prevent mitotic
catastrophe after DNA damage. Nature. 401:616–620. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Laronga C, Yang HY, Neal C and Lee MH:
Association of the cyclin-dependent kinases and 14-3-3 sigma
negatively regulates cell cycle progression. J Biol Chem.
275:23106–23112. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Phan L, Chou PC, Velazquez-Torres G,
Samudio I, Parreno K, Huang Y, Tseng C, Vu T, Gully C, Su CH, et
al: The cell cycle regulator 14-3-3 σ opposes and reverses cancer
metabolic reprogramming. Nat Commun. 6:75302015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perathoner A, Pirkebner D, Brandacher G,
Spizzo G, Stadlmann S, Obrist P, Margreiter R and Amberger A:
14-3-3sigma expression is an independent prognostic parameter for
poor survival in colorectal carcinoma patients. Clin Cancer Res.
11:3274–3279. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Neupane D and Korc M: 14-3-3sigma
modulates pancreatic cancer cell survival and invasiveness. Clin
Cancer Res. 14:7614–7623. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakamura Y, Oshima K, Naoi Y, Nakayama T,
Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y and Noguchi S:
14-3-3 σ expression is associated with poor pathological complete
response to neoadjuvant chemotherapy in human breast cancers.
Breast Cancer Res Treat. 134:229–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mikami T, Maruyama S, Abé T, Kobayashi T,
Yamazaki M, Funayama A, Shingaki S, Kobayashi T, Jun C and Saku T:
Keratin 17 is co-expressed with 14-3-3 sigma in oral carcinoma in
situ and squamous cell carcinoma and modulates cell proliferation
and size but not cell migration. Virchows Arch. 466:559–569. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roberts BJ, Reddy R and Wahl JK III:
Stratifin (14-3-3 σ) limits plakophilin-3 exchange with the
desmosomal plaque. PloS One. 8:e770122013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hatakeyama H, Mizumachi T, Sakashita T,
Kano S, Homma A and Fukuda S: Epithelial-mesenchymal transition in
human papillomavirus-positive and -negative oropharyngeal squamous
cell carcinoma. Oncol Rep. 32:2673–2679. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wakisaka N, Yoshida S, Kondo S, Kita M,
Sawada-Kitamura S, Endo K, Tsuji A, Nakanish Y, Murono S and
Yoshizaki T: Induction of epithelial-mesenchymal transition and
loss of podoplanin expression are associated with progression of
lymph node metastases in human papillomavirus-related oropharyngeal
carcinoma. Histopathology. 66:771–780. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kranjec C and Banks L: A systematic
analysis of human papillomavirus (HPV) E6 PDZ substrates identifies
MAGI-1 as a major target of HPV type 16 (HPV-16) and HPV-18 whose
loss accompanies disruption of tight junctions. J Virol.
85:1757–1764. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu JJ, Sammons MA, Donahue G, Dou ZX,
Vedadi M, Getlik M, Barsyte-Lovejoy D, Al-Awar R, Katona BW,
Shilatifard A, et al: Gain-of-function p53 mutants co-opt chromatin
pathways to drive cancer growth. Nature. 525:206–211. 2015.
View Article : Google Scholar : PubMed/NCBI
|
